Cessation of Dialysis Treatment in Reinbek and Geesthacht

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-01-01

Study Completion Date

2020-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Currently, approximately 80.000 patients with end stage renal disease (ESRD) in Germany undergo chronic renal replacement therapy, either as hemodialysis or peritonealdialysis. Since the nationwide registry for chronic dialysis patients (QuasiNiere) was terminated in 2006, no data exist from that time on regarding alterations in morbidity and mortality of patients with end stage renal disease in Germany.

With this study we start a single center prospective registry of all patients undergoing hemodialysis or peritonealdialysis therapy in our two nephrology departments Reinbek and Geesthacht. In these centers we perform approximately 34.000 hemodialysis sessions and supervise about 10.000 peritoneal treatment days of about 300 ESRD patients annually.

The aim of the study is to analyze all patients who stopped dialysis treatment in our centers due to death, kidney transplantation, recovery of renal function or other causes. Patients characteristics such as underlying renal diseases, duration of dialysis, co-morbidities as well as laboratory parameters will be recorded.

The data is collected with an Microsoft Access Database and analyzed by a statistician of the University of Luebeck (Germany). Power calculations revealed, that at least 200 patients were necessary to detect differences in particular interesting variables such as vascular access or the need of palliative care. During the last years at least 50 patients stopped chronic renal replacement therapy at out centers annually. Thus, the first interims evaluation is expected after 4 years.

The results of our study are important to estimate the development of patient age and renal diseases responsible for dialysis therapy in our centers. Moreover, the results may add important information to our internal quality assurance.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Open Versus Endovascular Revascularization in Patients With End-stage Renal Disease

NCT03293589

End-stage Renal Disease Critical Limb Ischemia

COMPLETED

Seasonal Differences in Home Dialysis Uptake and Initiating Dialysis in the Hospital

NCT04935827

Dialysis Peritoneal Dialysis Hospitalizations

COMPLETED

Prevalence of Non-adherence to Medication Among Patients on Chronic Hemodialysis

NCT03897231

Medication Adherence End Stage Renal Failure on Dialysis

COMPLETED

Arterial Calcifications in Nocturnal Hemodialysis and Renal Transplantation Versus Conventional Dialysis

NCT00950573

Kidney Disease

COMPLETED

Outcomes of Renal Access Arteriovenous Fistulas for Hemodialysis in Patients With Chronic Renal Failure

NCT04386954

End Stage Renal Disease

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Complication of Renal Dialysis Long-Term Disorder of Dialysis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with end stage renal disease and hemodialyis or peritonealdialysis
* Renal replacement therapy performed in our centers Reinbek or Geesthacht
* at least 4 weeks of dialysis treatment in any of our two treatment sites